

ASX ANNOUNCEMENT

27 February 2026

Appendix 4D and Half-Year Financial Report 31 December 2025

Half Year Report and Appendix 4D

In accordance with the requirements of the ASX Listing Rules, attached for release to the Market are the SomnoMed Limited (SomnoMed) half-year report for the six months ended 31 December 2025 and Appendix 4D. The previous corresponding period is the half-year ended 31 December 2024.

The information in this report should be read in conjunction with the most recent annual financial report.

The following will be released in conjunction with today's announcement:

- SomnoMed Half Year Results ASX Announcement;
- SomnoMed Half Year Results Presentation; and
- Appendix 4D.

Karen Borg and Amrita Blickstead, Co-CEOs, and Ye-Fei Guo, CFO, will host an investor presentation and Q&A on the half year results via a webinar commencing at 10am AEDT on Friday 27 February 2026.

Participants are invited to register for the webinar via the following link:

https://us06web.zoom.us/webinar/register/WN_uZTfqJmmSFKwOUSqj0L9lQ

Once you have registered you will receive an email confirming your attendance and information about joining the webinar.

Alternatively, participants may dial into the webcast for audio only:

Australian dial in numbers: +61 3 7018 2005 or +61 7 3185 3730 or +61 8 6119 3900 or +61 8 7150 1149 or +61 2 8015 6011

Meeting ID: 872 4858 6864 Passcode: 465126

Dial in numbers for other countries:

<https://us06web.zoom.us/join/9211111111?pwd=ODcyNDg1ODY4NjQ5ZG51DykvRNDZCnFXtRNpUTMMtoiaX6>

Authorised by the Company Secretary of SomnoMed Limited

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

Investor Enquiries

Investor Relations ir@somnomed.com



SOMNOMED LIMITED

ACN 003 255 221

HALF YEAR ENDED 31 DECEMBER 2025

RESULTS FOR ANNOUNCEMENT TO THE MARKET

	31 Dec 2025	31 Dec 2024	Movement	Increase/ (Decrease)
	\$'000	\$'000	\$'000	
Revenue from ordinary activities	\$60,717	\$53,709	\$7,008	13.1%
Revenue from ordinary activities, interest revenue and other income	\$60,741	\$53,720	\$7,021	13.0%
Profit from ordinary activities before tax attributable to members	\$2,108	\$1,506	\$602	40.0%
Profit/(loss) from ordinary activities after tax attributable to members	\$792	(\$106)	\$898	847.0%

Amounts rounded to nearest thousand dollars.

Commentary on results and other significant information

The Half-Year Report contains commentary on the half-year's results and the Company's operations and financial performance.

Additional dividend/distribution information

Details of dividends/distributions declared or paid during or subsequent to the half year ended 31 December 2025 are as follows:

Dividends/distributions	Amount per security	Franked amount per security	Record date for determining entitlements to the dividend
Final dividend	Nil	Nil	N/A
Interim dividend	Nil	Nil	N/A

The Board has resolved that no dividend will be paid for the half year ended 31 December 2025.



Table Of Contents

SECTION	TITLE	PAGE
1.	Directors' Report	2
2.	Auditor's Independence Declaration	4
3.	Financial Statements	5
4.	Notes to the Financial Statements	9
5.	Directors' Declaration	16
6.	Independent Audit Report	17
7.	Corporate Directory	19

SOMNOMED LIMITED

DIRECTORS' REPORT

Your Directors submit the financial report of the Consolidated Entity consisting of SomnoMed Limited ('the Company' or 'parent entity') and the entities it controlled ('the Consolidated Entity') for the half-year ended 31 December 2025.

The names of Directors in office at any time during or since the half-year are:

Guy Russo (Chairman)
Amrita Blickstead
Karen Borg
Benjamin Gisz
Michael Gordon
Andrew Price

Directors have been in office since the start of the financial year to the date of this report, unless otherwise stated.

Principal activity

There were no significant changes in the nature of the Consolidated Entity's principal activities during the half-year.

Operating results

The net profit after tax from continuing activities of the Consolidated Entity amounted to \$792,000 (31 December 2024: loss of \$106,000).

Dividends paid or recommended

There are no dividends paid, declared or recommended for the half-year ended 31 December 2025 (31 December 2024: nil).

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Consolidated Entity during the reporting period.

Events after reporting date

The Directors have not become aware of any matter or circumstance that has arisen since the end of the half-year to the date of this report that has significantly affected or may affect:

- (i) The operations of the Company and the entities that it controls
- (ii) The results of those operations, or
- (iii) The state of affairs of the Company in subsequent years.

Future developments

The Consolidated Entity will continue to produce and sell devices for the oral treatment of sleep related disorders in Australia and overseas.

Rounding of Amounts

The Company is of a kind referred to in *Corporations Instrument 2016/91*, issued by the Australian Securities and Investments Commission, relating to 'rounding off'. Amounts in this report have been rounded off in accordance with that Corporations instrument to the nearest thousand dollars.

SOMNOMED LIMITED DIRECTORS' REPORT

Auditor's independence declaration

The auditor's independence declaration for the half-year ended 31 December 2025 is set out on page 4 of these half-yearly accounts.

Signed in accordance with a resolution of the Board of Directors pursuant to section 306(3)(a) of the *Corporations Act 2001*.

A handwritten signature in black ink, appearing to read 'Guy Russo', is positioned above the printed name and title.

Guy Russo
Chairman

27 February 2026

DECLARATION OF INDEPENDENCE BY IAN HOOPER TO THE DIRECTORS OF SOMNOMED LIMITED

As lead auditor for the review of SomnoMed Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of SomnoMed Limited and the entities it controlled during the period.



Ian Hooper
Director

BDO Audit Pty Ltd

Sydney, 27 February 2026

SOMNOMED LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
AND OTHER COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	Note	31 December 2025 \$'000	31 December 2024 \$'000
Continuing operations			
Revenue from sale of goods and services, net of discounts	3	60,717	53,709
Cost of sales		(23,479)	(20,615)
Gross margin		37,238	33,094
Sales and marketing expenses		(11,810)	(11,011)
Administrative and other expenses		(10,662)	(9,295)
Corporate, research and business development expenses		(7,620)	(7,825)
Share based payments		(1,488)	(616)
Depreciation and amortisation expenses		(2,850)	(2,933)
Interest income	3	24	11
Finance costs		(215)	(128)
Unrealised foreign exchange (loss)/gain		(509)	209
Profit before income tax		2,108	1,506
Income tax expense attributable to operating profit		(1,316)	(1,612)
Profit /(loss) after income tax from continuing operations		792	(106)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign exchange translation difference for foreign operations		(607)	1,926
Other comprehensive (loss)/income for the half-year, net of tax		(607)	1,926
Total comprehensive income for the half-year attributable to the owners of SomnoMed Limited		185	1,820
Earnings per share			
Basic earnings per share (cents)		0.36	(0.05)
Diluted earnings per share (cents)		0.36	(0.05)

The above consolidated statement of profit and loss and other comprehensive income should be read in conjunction with the accompanying notes.

SOMNOMED LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	Note	31 December 2025	30 June 2025
		\$'000	\$'000
ASSETS			
Current assets			
Cash and cash equivalents		18,028	17,293
Trade and other receivables	5	18,148	18,421
Inventories		7,599	7,426
Total current assets		43,775	43,140
Non-current assets			
Trade and other receivables		54	55
Property, plant and equipment		7,078	6,982
Right-of-use assets		5,574	6,925
Intangible assets	6	21,666	21,488
Deferred tax assets		1,752	2,381
Total non-current assets		36,124	37,831
Total assets		79,899	80,971
LIABILITIES			
Current liabilities			
Trade and other payables	7	16,604	19,461
Provisions		4,012	4,517
Lease liabilities		2,225	2,488
Borrowings		282	344
Current tax liabilities		1,738	1,767
Total current liabilities		24,861	28,577
Non-current liabilities			
Provisions		896	810
Lease liabilities		3,667	4,745
Borrowings		439	449
Total non-current liabilities		5,002	6,004
Total liabilities		29,863	34,581
Net assets		50,036	46,390
EQUITY			
Issued capital	8	112,204	110,231
Reserves		15,034	14,153
Accumulated losses		(77,202)	(77,994)
Total equity		50,036	46,390

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

SOMNOMED LIMITED
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	Issued capital \$'000	Foreign currency translation reserve \$'000	Other reserves \$'000	Accumulated losses \$'000	Total \$'000
Balance at 1 July 2024	110,231	831	8,500	(74,537)	45,025
Loss after income tax expense for the half-year	-	-	-	(106)	(106)
Other comprehensive income for the half-year, net of tax	-	1,925	-	-	1,925
Total comprehensive income/(loss) for the half-year	-	1,925	-	(106)	1,819
<i>Transactions with owners in their capacity as owners:</i>					
Share option reserve on recognition of remuneration options	-	-	616	-	616
Balance at 31 December 2024	110,231	2,756	9,116	(74,643)	47,460
Balance at 1 July 2025	110,231	3,571	10,582	(77,994)	46,390
Profit after income tax expense for the half-year	-	-	-	792	792
Other comprehensive loss for the half-year, net of tax	-	(607)	-	-	(607)
Total comprehensive (loss)/income for the half-year	-	(607)	-	792	185
<i>Transactions with owners in their capacity as owners:</i>					
Proceeds from repayment of loan by Employee Share Trust	1,982	-	-	-	1,982
Share issue costs	(9)	-	-	-	(9)
Share option reserve on recognition of remuneration options	-	-	1,488	-	1,488
Balance at 31 December 2025	112,204	2,964	12,070	(77,202)	50,036

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

SOMNOMED LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	Note	31 December 2025	31 December 2024
		\$'000	\$'000
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		61,824	51,928
Payments to suppliers and employees (inclusive of GST)		(57,071)	(47,587)
Interest received	3	24	11
Interest paid		(26)	(20)
Income tax paid		(604)	(256)
Net cash inflow from operating activities		4,147	4,076
Cash flows from investing activities			
Payments for intangible assets		(1,016)	(737)
Payments for property, plant and equipment		(2,374)	(646)
Proceeds from disposal of property, plant and equipment		2	-
Net cash outflow from investing activities		(3,388)	(1,383)
Cash flows from financing activities			
Repayment of borrowings		(55)	(51)
Proceeds from repayment of loan by Employee Share Trust		1,982	-
Share issuance costs		(9)	(44)
Payment of finance leases		(1,620)	(1,430)
Net cash inflow /(outflow) from financing activities		298	(1,525)
Net increase in cash and cash equivalents		1,057	1,168
Cash at beginning of the period		17,293	16,179
Effect of exchange rate adjustment on cash and cash equivalents		(322)	1,151
Cash at end of the period		18,028	18,498

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

1. REPORTING ENTITY

SomnoMed Limited is a for-profit entity domiciled in Australia. The consolidated financial statements of the Company as at and for the half-year ended 31 December 2025 comprise the Company and its controlled entities (together referred to as the Consolidated Entity). The Consolidated Entity produces and sells devices for the oral treatment of sleep related disorders.

2. BASIS OF PREPARATION

2.1. Statement of compliance

These general purpose financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 *Interim Financial Reporting*.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

2.2. New, revised or amending Accounting Standards and Interpretations adopted

The Consolidated Entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. There was no material effect to the financial report due to this implementation.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The following illustrative examples have been issued during 2025 with no effective date:

On 28 November 2025, the IASB issued *Disclosures about Uncertainties in the Financial Statements* – Illustrative examples, which amended multiple IFRS Accounting Standards to include illustrative examples demonstrating how companies can apply IFRS Accounting Standards when reporting the effects of uncertainties in their financial statements. The illustrative examples are accompanying materials to IFRS Accounting Standards and do not have an effective date. The IASB had issued a near-final staff draft of the illustrative examples in July 2025. The Group has considered these illustrative examples in its preparation of the consolidated financial statements and no additional disclosures or changes in presentation were considered necessary.

The following amendments are effective for the period beginning 1 January 2027:

AASB 18 Presentation of Financial Statements which will replace *AASB 101 Presentation of Financial Statements* comes into effect for annual reporting periods beginning on or after 1 January 2027 and is expected to bring significant changes to the structure and presentation of financial disclosures.

The Company is currently assessing the implications of these changes and preparing for a smooth transition to ensure compliance and maintain financial reporting integrity.

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

3. REVENUE AND OTHER INCOME	31 December 2025	31 December 2024
	\$'000	\$'000
Operating activities		
Revenue from sale of goods and services, net of discounts	60,717	53,709
Interest income	24	11
Total revenue and other income	60,741	53,720

4. PROFIT BEFORE INCOME TAX FOR THE PERIOD	31 December 2025	31 December 2024
	\$'000	\$'000
Profit before income tax includes the following specific expenses:		
Employee benefits expense	22,055	24,838
Research and development expenditure	925	708

5. TRADE AND OTHER RECEIVABLES	31 December 2025	30 June 2025
	\$'000	\$'000
Current		
Trade and other receivables	15,454	14,206
Less: Allowance for expected credit losses	(92)	(110)
Net trade and other receivables	15,362	14,096
Prepayments	2,786	4,325
Total trade and other receivables	18,148	18,421

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

6. INTANGIBLE ASSETS

	Patents & trademarks \$'000	Product development \$'000	Software \$'000	Goodwill \$'000	Total \$'000
30 June 2025					
At cost	2,201	14,226	6,061	7,048	29,536
Accumulated amortisation	(1,854)	(1,342)	(4,852)	-	(8,048)
Carrying amount	347	12,884	1,209	7,048	21,488
31 December 2025					
At cost	2,175	14,934	6,127	6,897	30,133
Accumulated amortisation	(1,887)	(1,414)	(5,166)	-	(8,467)
Carrying amount	288	13,520	961	6,897	21,666
Movement for the period:					
Balance at 1 July 2024	426	11,853	1,695	6,343	20,317
Additions	15	1,243	490	-	1,748
Amortisation expenses	(121)	(212)	(979)	-	(1,312)
Foreign exchange impact	27	-	3	705	735
Balance at 30 June 2025	347	12,884	1,209	7,048	21,488
Additions	-	732	94	-	826
Amortisation expenses	(55)	(71)	(339)	-	(465)
Foreign exchange impact	(4)	(25)	(3)	(151)	(183)
Balance at 31 December 2025	288	13,520	961	6,897	21,666

7. TRADE AND OTHER PAYABLES

	31 December 2025 \$'000	30 June 2025 \$'000
Trade payables	6,349	6,635
Other payables and accruals	10,255	12,825
Total trade and other payables	16,604	19,460

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

8. ISSUED CAPITAL

Share capital in company accounts	31 December 2025 \$'000	Number of Ordinary shares	30 June 2025 \$'000	Number of Ordinary shares
Issued capital at the beginning of the period	110,231	211,909,753	110,231	211,909,753
Movement during the period				
Reduction of shares held by EST that were treated as options in accounts	1,982	2,860,000	-	-
Less: Issue costs	(9)	-	-	-
Shares issued from exercise of ZEPO's	-	2,075,000	-	-
Balance of share capital in company accounts at end of the period for accounting purposes	112,204	216,844,753	110,231	211,909,753
EST shares on issue*		1,338,500		4,198,500
Total shares on issue		218,183,253		216,108,253

* Shares held by Employee Share Trust ('EST') for executives to acquire shares in the Company by utilising funds advanced by the Company and are treated as options in these accounts. Employee Share Trust loan balance at period end \$2,237,000 (30 June 2025: \$6,992,000).

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

9. SHARE BASED PAYMENTS

9.1. Details of the share options outstanding during the period are as follows:

	31 December 2025		30 June 2025	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Opening balance	16,197,500	\$0.73	8,117,500	\$1.40
Granted during the period	7,025,500	\$0.18	8,080,000	\$0.18
Exercised during the period	(2,075,000)	\$Nil	-	-
Reduction of shares held by EST that were treated as options in accounts	(2,860,000)	\$0.70	-	-
Lapsed during the period	(346,000)	\$2.00	-	-
Outstanding at the end of the period*	17,942,000	\$0.67	16,197,500	\$0.73
Exercisable at the end of the period	7,880,982		5,698,500	

*Shares treated as options for these accounts are included 1,338,500 (30 June 2025: 4,198,500)

9.2. Details of options granted during the period	ZEPOs granted to Co-CEOs	Options granted to Co-CEOs	Options issued to NEDs	Options granted to employees
Grant date	1 July 2025	16 September 2025	16 September 2025	Various
Number of options	1,200,000	1,400,000	1,000,000	3,425,500
Weighted average share price	\$0.27	\$0.70	\$0.70	\$0.84
Weighted average exercise price	\$Nil	\$0.70	\$1.00	\$Nil
Expected volatility	61%	60%	60%	60%
Expected life in years	2.25	2.00	4.00	Average 5.24
Risk-free rate	4.35%	4.23%	4.23%	4.38%

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

10. SEGMENT REPORT

10.1. Primary reporting – business segments

The Consolidated Entity produces and sells devices for the oral treatment of sleep related disorders primarily in the Asia Pacific region, North America and Europe.

The Consolidated Entity has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (chief operating decision makers) in assessing performance and determining the allocation of resources. The Consolidated Entity is managed primarily on the basis of geographical segments and the operating segments are therefore determined on the same basis.

The Consolidated Entity's operations during the period is the production and sale of devices for the oral treatment of sleep related disorders, which is the only business segment.

Basis of accounting for purposes of reporting by operating segments

Accounting policies adopted

Unless stated otherwise, all amounts reported to the Board of Directors as the chief operating decision maker with respect to operating segments are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of the Consolidated Entity.

Unallocated items

The following items of revenue and expenses are not allocated to operating segments as they are not considered part of the core operations of any segment: derivatives and foreign exchange gains and losses; corporate, research and development expenses; share based payments; and other one-off expenses.

10.2. Secondary reporting – geographical segments

Geographical location:	North America	Europe	Asia Pacific	Consolidated Entity
31 December 2024	\$'000	\$'000	\$'000	\$'000
Total revenue	22,066	28,531	12,914	63,511
Intersegment eliminations	(135)	(524)	(9,143)	(9,802)
External revenue	21,931	28,007	3,771	53,709
Segment net profit/(loss) before tax	7,648	6,189	(841)	12,996
Unallocated expense items	-	-	(8,440)	(8,440)
Depreciation and amortisation expenses	(269)	(916)	(1,748)	(2,933)
Interest income	-	4	7	11
Finance cost	(31)	(68)	(29)	(128)
Profit/(loss) before tax	7,348	5,209	(11,051)	1,506
Income tax expense	(843)	(664)	(105)	(1,612)
Profit/(loss) after tax	6,505	4,545	(11,156)	(106)
Total assets	11,924	29,529	33,540	74,993
Total liabilities	4,611	14,129	8,794	27,534

SOMNOMED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

10. SEGMENT REPORT (continued)

10.2 Secondary reporting – geographical segments

Geographical location:	North America	Europe	Asia Pacific	Consolidated Entity
31 December 2025	\$'000	\$'000	\$'000	\$'000
Total revenue	24,536	33,658	14,276	72,470
Intersegment eliminations	(161)	(931)	(10,661)	(11,753)
External revenue	24,375	32,727	3,615	60,717
Segment net profit/(loss) before tax	7,950	7,599	(640)	14,909
Unallocated expense items	-	(346)	(9,413)	(9,759)
Depreciation and amortisation expenses	(247)	(1,050)	(1,554)	(2,851)
Interest income	-	1	23	24
Finance cost	(20)	(80)	(115)	(215)
Profit/(loss) before tax	7,683	6,124	(11,699)	2,108
Income tax expense	(638)	(527)	(151)	(1,316)
Profit/(loss) after tax	7,045	5,597	(11,850)	792
Total assets	10,437	29,006	40,455	79,898
Total liabilities	4,060	13,883	11,919	29,862

11. EVENTS OCCURRING AFTER THE REPORTING DATE

The Directors have not become aware of any other matter or circumstance that has arisen since the end of the financial half-year ended 31 December 2025 to the date of this report that has significantly affected or may affect:

- (i) The operations of the Company and the entities that it controls
- (ii) The results of those operations, or
- (iii) The state of affairs of the Company in subsequent years.

SOMNOMED LIMITED DIRECTORS' DECLARATION

In the Directors' opinion:

- the attached financial statements and notes comply with the *Corporations Act 2001*, Australian Accounting Standard AASB 134 *Interim Financial Reporting*, the *Corporations Regulations 2001* and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Consolidated Entity's financial position as at 31 December 2025 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the *Corporations Act 2001*.

On behalf of the Directors



Ms Amrita Blickstead
Co-Chief Executive Officer



Ms Karen Borg
Co-Chief Executive Officer

27 February 2026

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of SomnoMed Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of SomnoMed Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- i. Giving a true and fair view of the Group's financial position as at 31 December 2025 and of its financial performance for the half-year ended on that date; and
- ii. Complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.



Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit Pty Ltd

BDO

A handwritten signature in black ink, appearing to read 'Ian Hooper', written over a faint, illegible line of text.

Ian Hooper
Director

Sydney, 27 February 2026

CORPORATE DIRECTORY

SomnoMed Limited

ACN 003 255 221

Registered office and principal place of business

Level 3, 20 Clarke St, Crows Nest 2065

Telephone: (02) 9467 0400

Directors

Guy Russo Non-Executive Chairman

Amrita Blickstead Executive Director

Karen Borg Executive Director

Benjamin Gisz Non-Executive Director

Michael Gordon Non-Executive Director

Andrew Price Non-Executive Director

Chief Executive Officers

Amrita Blickstead

Karen Borg

Chief Financial Officer

Ye-Fei Guo

Company Secretary

Terence Flitcroft

Patent attorneys

Spruson & Ferguson

Bankers

HSBC

Westpac Banking Corporation

Auditors

BDO Audit Pty Ltd (Australia)

Share registry

Boardroom Pty Limited

SYDNEY NSW 2000

(GPO Box 3993 Sydney NSW 2001)

Telephone (02) 9290 9600

Facsimile (02) 9279 0664

www.boardroomlimited.com.au

Company website

www.somnomed.com.au

Stock exchange listing

SomnoMed Limited shares are listed on the Australian Securities Exchange (ASX code: SOM).